Inequalities in pharmacologic treatment of spasticity in Sweden – health economic consequences of closing the treatment gap

Table 1 Epidemiology of spasticity

Condition	Prevalence/100,000	Prevalence disabling spasticity
Stroke	715 [12]	17% [13,14,15]
CP	215 [16]	23% [17]
MS	190 [18]	33% [19]
TBI	150 [20]	19% [21]
SCI	32 [22, 23]	31% [24, 25]

Mean prevalence of disabling spasticity for all diagnoses = 271/100,000 ^a)
Abbreviations: MS (multiple sclerosis), CP (cerebral palsy), SCI (spinal cord injury), TBI (traumatic brain injury)
^aAssuming an even distribution in disabling spasticity across healthcare regions

ISSN: 2191-1991